1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Hemorrhage in PRES: relationship to clinical associations and blood pressure at toxicity
Toxicity Association Total No. Pts with PRES Patients with PRES and Hemorrhage
No. Hemorrhage (%) Blood Pressure in Pts with PRES Hemorrhage
Normotensive (MAP ≤ 105) Mild HTN (MAP, 106–115) Severe HTN (MAP ≥ 116)
Immunosuppression^‡ 50 11 (22.0) 3 1 7
    Solid-organ transplant 34 4 (11.8) 2 1 1
    Allo-BMT 15 7 (46.7) 1 0 6
    Other^* 1 0 (0.0) – – –
Infection/sepsis/shock 52 6 (11.5) 4 1 1
Autoimmune 12 2 (16.7) 0 0 2
Chemotherapy 10 1 (10.0) 0 1 0
Eclampsia^† 18 1 (5.6) 0 0 1
Unknown 9 2 (22.2) 0 0 2
Total 151 23 (15.2) 7 3 13
Note:—Pts indicates patients; CsA, cyclosporine; HTN, hypertension; –, none; PRES, posterior reversible encephalopathy syndrome; MAP, mean arterial pressure; FK-506, tacrolimus; Allo-BMT, allogeneic bone marrow transplantation.
* A single patient with psoriasis on cyclosporine.
† Patients with eclampsia and delayed eclampsia.
‡ Transplant, on cyclosporine, or tacrolimus (FK-506).